Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subanesthetic-dose Esketamine in Modified Electroconvulsive Therapy for Adolescents With Severe Depression
NCT07247968Phase 1Recruiting
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Esketamine + MECT with Placebo + MECT (2 arms). Primary endpoint: Treatment response rate of depressive symptoms. Started Nov 2025; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07247968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247968.